Ventiv's Clinical Services division has joined with India's largest
domestic contract research organization (CRO), SIRO Clinpharm, to
provide India-based clinical data management services, offering
pharma and biotech companies...
Eisai has become the first Japanese drugmaker to set up a dedicated
subsidiary in India in order to tap into local expertise in
manufacturing and research, according to local press reports.
Ranbaxy Laboratories (RLL) has opened its third state-of-the-art
drug discovery research centre in India, boosting the country's
profile as a key destination for pharmaceutical-related R&D by
drug companies, who are attracted...
Pfizer has revealed that it is set to outsource some of its
technology jobs to India, harnessing the country's IT
infrastructure to focus more on clinical trial and other
R&D-related information management.
Agilent Technologies has announced plans to introduce its DNA
microarray-based genomics technology to India, reaffirming its
plans to expand its presence in medical research, drug discovery,
agro-biotech.The Indian microarray market...
India now has its sights firmly set on the biotechnology industry,
having already emerged as a dynamic new player in the global market
for chemical-based pharmaceuticals, reports Phil Taylor.
India's new patent law, that will prevent domestic pharmaceutical
manufacturers from making low-cost generic copies of in-patent
drugs - has finally been passed by the lower house of the country's
parliament, writes Phil...
China and India are forecasted as the most exciting prospects for
European pharmaceutical and biotechnology companies. Despite having
over a third of the world's population, Asia accounts for only one
fifth of global pharmaceutical...
The Indian pharmaceutical sector has begun its seismic shake-up
following the introduction of new laws granting patent protection
to medicines on 1 January.
India is gearing up for the introduction of new legislation on
intellectual property that will bring it into line with its World
Trade Organisation commitments.
India's Ajanta Pharma has said that it may re-enter the market for
bulk manufacture of active pharmaceutical ingredients (APIs),
despite pulling out of the sector in the late 1990s.
India's Dishman Pharmaceuticals and Chemicals has set up a company
specialising in the contract manufacture of active pharmaceutical
ingredients (APIs) and intermediates that is specifically aimed at
winning business from foreign...
US-based biotechnology company Human Genome Sciences is planning to
set up the first protein manufacturing facility in India in
collaboration with local companies.
Chemicals company Sigma-Aldrich is to build an $8 million (€6.5m)
laboratory-scale production facility for pharmaceuticals in
Hyderabad, India, that will act as a feeder site for its plants
elsewhere.
The Indian government has proposed draconian new penalties for
individuals found making counterfeit pharmaceuticals, after a
number of fatalities associated with bootleg drugs.